Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
| Business Activity | PASS |
| Debt Ratio (0.08%) | PASS |
| Cash Ratio (0.75%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-14 | -0.15 | Pending | -- |
| 2026-05-14 | -0.15 | -0.17 | -13.3% |
| 2026-03-11 | -0.14 | 1.48 | +1157.1% |
| 2025-11-06 | -0.15 | -0.09 | +41.9% |
| 2025-08-14 | -0.17 | -0.23 | -35.3% |
| 2025-05-08 | -0.20 | -0.21 | -2.4% |
| 2025-03-06 | -0.25 | -0.26 | -4.0% |
| 2024-11-14 | -0.44 | 0.33 | +175.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3.1M | -$7.5M | -$5.4M | $1.8M | -$5.7M | -0.17 |
| 2025-12-31 | $3.3M | $70.8M | -$5.2M | $1.9M | -$5.5M | 1.66 |
| 2025-09-30 | $3.3M | -$3.9M | $618.0K | $1.9M | -$4.4M | -0.09 |
| 2025-06-30 | $6.3M | -$9.6M | -$8.2M | $3.1M | -$5.9M | -0.23 |
| 2025-03-31 | $3.0M | -$3.9M | -$827.0K | $1.4M | -$4.2M | -0.10 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-03-10 | MILLS CHARLES RANDAL | Chief Executive Officer | 27,084 | -- |
| 2026-03-10 | FERGUSON MATTHEW B | Chief Financial Officer | 12,500 | -- |
| 2026-03-10 | WILLIAMS MICHELLE LEROUX | Officer | 12,500 | -- |
| 2026-01-30 | NEELS GUIDO J | Director | 20,000 | $20.8K |
| 2026-01-30 | RAKIN KEVIN L | Director and Beneficial Owner of more than 10% of a Class of Security | 70,000 | $74.2K |
| 2026-01-29 | NEELS GUIDO J | Director | 30,000 | $31.8K |
| 2025-12-17 | MAKES BRIGID A | Director | 25,000 | $13.0K |
| 2025-12-17 | RAKIN KEVIN L | Director and Beneficial Owner of more than 10% of a Class of Security | 50,000 | $26.0K |
| 2025-12-17 | MILLS CHARLES RANDAL | Chief Executive Officer | 3,000 | $1.5K |
| 2025-12-17 | FERGUSON MATTHEW B | Chief Financial Officer | 60,000 | $31.8K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| AIGH Capital Management LLC | 3.6M | $4.2M | 0.1% |
| Nantahala Capital Management, LLC | 3.2M | $3.7M | 0.1% |
| Knollwood Investment Advisory, LLC | 2.6M | $3.0M | 0.1% |
| SilverArc Capital Management, LLC | 2.5M | $2.9M | 0.1% |
| Vanguard Capital Management LLC | 1.0M | $1.2M | 0.0% |
| Perkins Capital Management, Inc. | 756.9K | $878.0K | 0.0% |
| Geode Capital Management, LLC | 293.4K | $340.3K | 0.0% |
| Corient Private Wealth LLC | 249.0K | $288.9K | 0.0% |
| Birchview Capital, LP | 165.1K | $191.5K | 0.0% |
| Blackrock Inc. | 122.1K | $141.6K | 0.0% |
$11.7M
1.79
0.756
1
$12.3M
$3.9M
1.00
1.81
0.0%
25
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-14 | $-0.15 | Pending | — |
| 2026-05-14 | $-0.15 | $-0.17 | -13.3% |
| 2026-03-11 | $-0.14 | $1.48 | +1157.1% |
| 2025-11-06 | $-0.15 | $-0.09 | +41.9% |
| 2025-08-14 | $-0.17 | $-0.23 | -35.3% |
| 2025-05-08 | $-0.20 | $-0.21 | -2.4% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($5.00, 1 analysts) | |||
| 10 | $10.40 | +$39.60 (381%) | 24.8R |
| 50 | $52.00 | +$198.00 (381%) | 24.8R |
| 100 | $104.00 | +$396.00 (381%) | 24.8R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| STUB | 0.199 |
| AVO | 0.196 |
| KRYS | 0.184 |
| ELWT | 0.181 |
| 6004.SR | 0.175 |
| Ticker | Correlation |
|---|---|
| INFIQ | -0.199 |
| MGRT | -0.137 |
| SUNC | -0.135 |
| PLBL | -0.133 |
| KBNT | -0.122 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.